0000000302cnt-2013-11_gpc_obesidad-2013

More documents

Recommendations

Info

Guía de Práctica Clínica Nacional sobre Diagnóstico y Tratamiento de la Obesidad / Versión preliminar Guía de Práctica Clínica Nacional sobre Diagnóstico y Tratamiento de la Obesidad / Versión preliminar 139 et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61. 132. XENical in the Prevention of Diabetes in Obese Subjects ( XENDOS ) Study. 2004;27(1). 133. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes. Obes. Metab. [Internet]. 2002 Nov;4(6):415–23. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/12406041 134. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet [Internet]. 1998 Jul;352(9123):167–72. Available from: http://linkinghub.elsevier.com/retrieve/pii/ S0140673697115094 135. Bakris G, Calhoun D, Egan B, Hellmann C. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension Michael Dolker d and Iris Kingma d on behalf of the orlistat and resistant hypertension investigators. 2002;2257–67. 136. Shekelle PG, Morton SC, Maglione MA, Suttorp M, Tu W, Li Z, Maggar M, Mojica WA SL, V. S. Pharmacological and Surgical Treatment of Obesity. Evidence Report/Technology Assessment No. 103. (Prepared by the Southern California–RAND Evidence-Based Practice Center, Santa Monica, CA, under contract Number 290-02-0003.). 137. Davidson MH, Hauptman J, Digirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years. 1999;281(3). 138. Rissanen a, Lean M, Rössner S, Segal KR, Sjöström L. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int. J. Obes. Relat. Metab. Disord. [Internet]. 2003 Jan [cited 2013 Sep 27];27(1):103–9. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/12532161 139. Sjöström L, Lindroos A-K, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. [Internet]. 2004 Dec 23 [cited 2013 Oct 29];351(26):2683–93. Available from: http:// www.ncbi.nlm.nih.gov/pubmed/15616203 140. Des V, Modes T, Sant IEN. Surgical treatment of morbid obesity. 141. Flum DR, Dellinger EP. Impact of gastric bypass operation on survival: a population-based analysis. J. Am. Coll. Surg. [Internet]. 2004 Oct [cited 2013 Nov 9];199(4):543–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15454136 142. Shekelle PG, Morton SC, Maglione M, Suttorp M, Tu W, Li Z, et al. Pharmacological and surgical treatment of obesity. Evid. Rep. Technol. Assess. (Summ). [Internet]. 2004 Jul;(103):1–6. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/15526396 143. Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Sugarman HJ, et al. Meta-analysis: surgical treatment of obesity. Ann. Intern. Med. [Internet]. 2005 Apr 5 [cited 2013 Oct 25];142(7):547–59. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15809466 144. Colquitt J, Clegg A, Loveman E, Royle P, Sidhu MK. Surgery for morbid obesity. Cochrane database Syst. Rev. [Internet]. 2005 Jan [cited 2013 Oct 21];(4):CD003641. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16235331 145. Vest AR, Heneghan HM, Agarwal S, Schauer PR, Young JB. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart [Internet]. 2012 Dec [cited 2013 Oct 22];98(24):1763–77. Available from: http:// www.ncbi.nlm.nih.gov/pubmed/23077152 146. Padwal R, Klarenbach S, Wiebe N, Birch D, Karmali S, Manns B, et al. Bariatric surgery: a systematic review and network meta-analysis of randomized trials. Obes. Rev. [Internet]. 2011 Aug [cited 2013 Sep 27];12(8):602–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21438991 147. Camberos-Solis, A. Jiménez-Cruz MB-G y JMC. Efectividad y seguridad a largo plazo del bypass gástrico en “Y” de Roux y de la banda gástrica: revisión sistemática. Nutr Hosp. 2010;25:964–70.
140 Guía de Práctica Clínica Nacional sobre Diagnóstico y Tratamiento de la Obesidad 148. Leslie DB, Dorman RB, Serrot FJ, Swan TW, Kellogg TA, Torres-Villalobos G, et al. Efficacy of the Roux-en-Y gastric bypass compared to medically managed controls in meeting the American Diabetes Association composite end point goals for management of type 2 diabetes mellitus. Obes. Surg. [Internet]. 2012 Mar [cited 2013 Oct 29];22(3):367–74. Available from: http:// www.ncbi.nlm.nih.gov/pubmed/21918925 149. Gill RS, Birch DW, Shi X et al. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis. 2010;6:707–13. 150. Neovius M, Narbro K, Keating C, Peltonen M, Sjöholm K, Agren G, et al. Health care use during 20 years following bariatric surgery. JAMA [Internet]. 2012 Sep 19;308(11):1132–41. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/22990272 151. Carlsson LMS, Peltonen M, Ahlin S, Anveden Å, Bouchard C, Carlsson B, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N. Engl. J. Med. [Internet]. 2012 Aug 23 [cited 2013 Sep 22];367(8):695–704. Available from: http:// www.ncbi.nlm.nih.gov/pubmed/22913680 152. Pontiroli AE, Morabito A. Long-term prevention of mortality in morbid obesity through bariatric surgery. a systematic review and metaanalysis of trials performed with gastric banding and gastric bypass. Ann. Surg. [Internet]. 2011 Mar [cited 2013 Nov 9];253(3):484–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21245741 153. Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: cosponsored by american association of clinical endocrinologists, the obesity society, and american society fo. Endocr. Pract. [Internet]. 2013 [cited 2013 Sep 25];19(2):337–72. Available from: http:// www.ncbi.nlm.nih.gov/pubmed/23529351 154. Brethauer SA, Hammel JP SP. Systematic review of sleeve gastrectomy as staging and primary bariatric procedure. Surg Obes Relat Dis. 2009;5:469–75. 155. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr. 1992;55(2suppl):615S–619S. 156. O’Brien PE, Dixon JB LC et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med. 2006;144:625–33. 157. Fontbonne A, Charles MA J-VI. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care. 1996;19:920-6. 1996;19:920–6. 158. Gambineri A, Patton L, Vaccina A et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab. 2006;91:3970–80. 159. Crandall J, Schade D et al. Diabetes Prevention Program Research Group. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci. 2006;61:1075–81. 160. Wilding J, Van Gaal L, Rissanen A, Vercruysse F FM. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord. 2004;28:1399–410. 161. Kramer CK, Leitão CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes. Rev. [Internet]. 2011 May [cited 2013 Sep 20];12(5):e338– 47. Available from: http://www.ncbi.nlm.nih. gov/pubmed/21438989 162. Igho Onakpoya, Shao Kang Hung, Rachel Perry, BarbaraWider and EE. The Use of Garcinia Extract (Hydroxycitric Acid) as a Weight loss Supplement: A Systematic Review andMeta- Analysis of Randomised Clinical Trials. Penins. Med. Sch. Univ. Exet. [Internet]. 2010; Available from: igho.onakpoya@pcmd.ac.uk 163. Shekelle PG, Hardy ML MS. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003;289:1537–45. 164. Pittler MH, Stevinson C EE. Chromium picolinate for reducing body weight: meta-analysis of randomized trials. Int J Obes Relat Metab Disord. 2003;27:522–9.
Page 1 and 2:
Guía de Práctica Clínica Naciona
Page 3 and 4:
2 Guía de Práctica Clínica Nacio
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
10 Guía de Práctica Clínica Naci
Page 14 and 15:
Marco Teórico
Page 16 and 17:
Page 18 and 19:
Page 20:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90: 88 Guía de Práctica Clínica Naci
Page 101 and 102: 100 Guía de Práctica Clínica Nac
Page 139: 138 Guía de Práctica Clínica Nac
show all

0000000302cnt-2013-11_gpc_obesidad-2013

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?